Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$432/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

LSL Pharma Group Inc. (V:LSL)

Business Focus: Pharmaceuticals (NEC)

Sector:  Healthcare Industry:  Pharmaceuticals
 
Company Contact
Address: 540, rue d'Avaugour, Office 1800
BOUCHERVILLE QC J4B 0G6
Tel: N/A
Website: N/A
IR: N/A
Key People
Marcel R. Tremblay
Chairman of the Board
Alain Larochelle
President, Chief Executive Officer, Director
Luc Mainville
Chief Financial Officer, Senior Vice President
Pierre-Hubert Seguin
Secretary, Director
   
Business Overview
LSL Pharma Group Inc. is a Canadian integrated pharmaceutical company. The Company is specializing in the development, manufacturing and distribution of natural health products and dietary supplements in solid dosage forms, as well as sterile ophthalmic pharmaceutical products. The Company's subsidiaries include Steri-Med Pharma Inc., LSL Laboratory Inc. and Groupe Immobilier LSL inc.
Financial Overview
For the fiscal year ended 31 December 2023, LSL Pharma Group Inc revenues totaled C$10M. Net loss totaled to C$8.5M. Results are not comparable due to year end change.
Reporting Currency: Canadian Dollars
Enterprise value: $70.36M as of Dec 31, 2023
Annual revenue (TTM): $10.03M as of Dec 31, 2023
EBITDA (TTM): -$0.58M as of Dec 31, 2023
Net annual income (TTM): -$8.47M as of Dec 31, 2023
Free cash flow (TTM): -$8.09M as of Dec 31, 2023
Net Debt Last Fiscal Year: $16.26M as of Dec 31, 2023
Shares outstanding: 108,240,370 as of Apr 25, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization